Super Religare expands Rosetta’s MicroRNA assay coverage
This article was originally published in Clinica
Executive Summary
Rosetta Genomics has broadened its global sales network by signing an exclusive distribution deal with Super Religare Laboratories (SRL), said to be the largest Indian diagnostics network. The new partnership will see SRL make Rosetta’s range of miRview tests available in India, Saudi Arabia, Qatar and the UAE. The miRview portfolio includes a test for identifying the primary tumour site in metastatic cancer patients and patients with cancer of unknown primary, another for differentiating squamous from non-squamous non-small cell lung cancer and a test for distinguishing mesothelioma from other carcinomas in the lung. Financial details of the deal were not disclosed.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals